426 related articles for article (PubMed ID: 36692880)
1. Telemedicine Use and Quality of Opioid Use Disorder Treatment in the US During the COVID-19 Pandemic.
Hailu R; Mehrotra A; Huskamp HA; Busch AB; Barnett ML
JAMA Netw Open; 2023 Jan; 6(1):e2252381. PubMed ID: 36692880
[TBL] [Abstract][Full Text] [Related]
2. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
3. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
[TBL] [Abstract][Full Text] [Related]
4. Use of Telemedicine and Quality of Care Among Medicare Enrollees With Serious Mental Illness.
Wilcock AD; Huskamp HA; Busch AB; Normand ST; Uscher-Pines L; Raja PV; Zubizarreta JR; Barnett ML; Mehrotra A
JAMA Health Forum; 2023 Oct; 4(10):e233648. PubMed ID: 37889483
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
Wakeman SE; Larochelle MR; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
JAMA Netw Open; 2020 Feb; 3(2):e1920622. PubMed ID: 32022884
[TBL] [Abstract][Full Text] [Related]
6. Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees.
Hammerslag LR; Mack A; Chandler RK; Fanucchi LC; Feaster DJ; LaRochelle MR; Lofwall MR; Nau M; Villani J; Walsh SL; Westgate PM; Slavova S; Talbert JC
JAMA Netw Open; 2023 Oct; 6(10):e2336914. PubMed ID: 37851446
[TBL] [Abstract][Full Text] [Related]
7. Trends in Opioid Use Disorder Outpatient Treatment and Telehealth Utilization Before and During the COVID-19 Pandemic.
Tormohlen KN; Eisenberg MD; Fingerhood MI; Yu J; McCourt AD; Stuart EA; Rutkow L; Quintero L; White SA; McGinty EE
Psychiatr Serv; 2024 Jan; 75(1):72-75. PubMed ID: 37461819
[TBL] [Abstract][Full Text] [Related]
8. Overall and Telehealth Addiction Treatment Utilization by Age, Race, Ethnicity, and Socioeconomic Status in California After COVID-19 Policy Changes.
Palzes VA; Chi FW; Metz VE; Sterling S; Asyyed A; Ridout KK; Campbell CI
JAMA Health Forum; 2023 May; 4(5):e231018. PubMed ID: 37204804
[TBL] [Abstract][Full Text] [Related]
9. An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic.
Hughes PM; Verrastro G; Fusco CW; Wilson CG; Ostrach B
J Rural Health; 2021 Jun; 37(3):467-472. PubMed ID: 33720447
[TBL] [Abstract][Full Text] [Related]
10. Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine.
Uscher-Pines L; Sousa J; Raja P; Mehrotra A; Barnett M; Huskamp HA
J Subst Abuse Treat; 2020 Nov; 118():108124. PubMed ID: 32893047
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
[TBL] [Abstract][Full Text] [Related]
12. Trends in Use of Medication to Treat Opioid Use Disorder During the COVID-19 Pandemic in 10 State Medicaid Programs.
Austin AE; Tang L; Kim JY; Allen L; Barnes AJ; Chang CH; Clark S; Cole ES; Durrance CP; Donohue JM; Gordon AJ; Huskamp HA; McDuffie MJ; Mehrotra A; Mohamoud S; Talbert J; Ahrens KA; Applegate M; Hammerslag LR; Lanier P; Tossone K; Zivin K; Burns ME
JAMA Health Forum; 2023 Jun; 4(6):e231422. PubMed ID: 37327009
[TBL] [Abstract][Full Text] [Related]
13. Initiating Opioid Use Disorder Medication via Telemedicine During COVID-19: Implications for Proposed Reforms to the Ryan Haight Act.
Huskamp HA; Riedel L; Uscher-Pines L; Busch AB; Barnett ML; Raja P; Mehrotra A
J Gen Intern Med; 2022 Jan; 37(1):162-167. PubMed ID: 34713386
[TBL] [Abstract][Full Text] [Related]
14. Gender differences in receipt of telehealth versus in person behavioral therapy, medication for opioid use disorder (MOUD), and 90-day MOUD retention during the pandemic: A retrospective veteran cohort study.
Livingston NA; Sarpong A; Sistad R; Roth C; Banducci AN; Simpson T; Hyde J; Davenport M; Weisberg R
J Subst Use Addict Treat; 2024 Jan; 156():209188. PubMed ID: 37866437
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and correlates of U.S. clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic.
Jones CM; Diallo MM; Vythilingam M; Schier JG; Eisenstat M; Compton WM
Drug Alcohol Depend; 2021 Aug; 225():108783. PubMed ID: 34049102
[TBL] [Abstract][Full Text] [Related]
16. Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder.
Weintraub E; Seneviratne C; Anane J; Coble K; Magidson J; Kattakuzhy S; Greenblatt A; Welsh C; Pappas A; Ross TL; Belcher AM
JAMA Netw Open; 2021 Aug; 4(8):e2118487. PubMed ID: 34448869
[TBL] [Abstract][Full Text] [Related]
17. Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic.
Mattocks KM; Moore DT; Wischik DL; Lazar CM; Rosen MI
J Subst Abuse Treat; 2022 Aug; 139():108777. PubMed ID: 35346533
[TBL] [Abstract][Full Text] [Related]
18. A qualitative study of patient experiences with telemedicine opioid use disorder treatment during COVID-19.
Lockard R; Priest KC; Gregg J; Buchheit BM
Subst Abus; 2022; 43(1):1150-1157. PubMed ID: 35499402
[No Abstract] [Full Text] [Related]
19. Use of Telehealth for Opioid Use Disorder Treatment in Safety Net Primary Care Settings: A Mixed-Methods Study.
Bailey SR; Wyte-Lake T; Lucas JA; Williams S; Cantone RE; Garvey BT; Hallock-Koppelman L; Angier H; Cohen DJ
Subst Use Misuse; 2023; 58(9):1143-1151. PubMed ID: 37170596
[No Abstract] [Full Text] [Related]
20. Telehealth Initiation of Buprenorphine for Opioid Use Disorder: Patient Characteristics and Outcomes.
Nguyen B; Zhao C; Bailly E; Chi W
J Gen Intern Med; 2024 Jan; 39(1):95-102. PubMed ID: 37670069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
